JP2011500718A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011500718A5 JP2011500718A5 JP2010530124A JP2010530124A JP2011500718A5 JP 2011500718 A5 JP2011500718 A5 JP 2011500718A5 JP 2010530124 A JP2010530124 A JP 2010530124A JP 2010530124 A JP2010530124 A JP 2010530124A JP 2011500718 A5 JP2011500718 A5 JP 2011500718A5
- Authority
- JP
- Japan
- Prior art keywords
- mva
- antigen
- polypeptide
- pap
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 claims description 61
- 239000000427 antigen Substances 0.000 claims description 37
- 102000036639 antigens Human genes 0.000 claims description 37
- 108091007433 antigens Proteins 0.000 claims description 37
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 30
- 229920001184 polypeptide Polymers 0.000 claims description 29
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 29
- 229940123237 Taxane Drugs 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 16
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 16
- 230000028993 immune response Effects 0.000 claims description 14
- 230000002163 immunogen Effects 0.000 claims description 13
- 101001035654 Homo sapiens 28 kDa heat- and acid-stable phosphoprotein Proteins 0.000 claims description 12
- 101000785915 Homo sapiens Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 2 Proteins 0.000 claims description 12
- 101000735427 Homo sapiens Poly(A) RNA polymerase, mitochondrial Proteins 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 206010060862 Prostate cancer Diseases 0.000 claims description 11
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 11
- 230000002476 tumorcidal effect Effects 0.000 claims description 11
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 9
- 101000605534 Homo sapiens Prostate-specific antigen Proteins 0.000 claims description 9
- 101000592517 Homo sapiens Puromycin-sensitive aminopeptidase Proteins 0.000 claims description 9
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 9
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims description 8
- 102000007066 Prostate-Specific Antigen Human genes 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 7
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 6
- 230000037452 priming Effects 0.000 claims description 6
- 239000002773 nucleotide Substances 0.000 claims description 5
- 125000003729 nucleotide group Chemical group 0.000 claims description 5
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 4
- 229930012538 Paclitaxel Natural products 0.000 claims description 4
- 229960003668 docetaxel Drugs 0.000 claims description 4
- 229960001592 paclitaxel Drugs 0.000 claims description 4
- 108010043671 prostatic acid phosphatase Proteins 0.000 claims description 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 4
- 108091029795 Intergenic region Proteins 0.000 claims description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 108010071652 human kallikrein-related peptidase 3 Proteins 0.000 claims description 2
- 102000007579 human kallikrein-related peptidase 3 Human genes 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 238000001514 detection method Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000010658 metastatic prostate carcinoma Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 15
- 102100037850 Interferon gamma Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 230000005867 T cell response Effects 0.000 description 3
- 241000282412 Homo Species 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96089307P | 2007-10-18 | 2007-10-18 | |
| US60/960,893 | 2007-10-18 | ||
| PCT/US2008/080229 WO2009052328A1 (en) | 2007-10-18 | 2008-10-16 | Use of mva to treat prostate cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011500718A JP2011500718A (ja) | 2011-01-06 |
| JP2011500718A5 true JP2011500718A5 (enExample) | 2011-10-20 |
| JP5669581B2 JP5669581B2 (ja) | 2015-02-12 |
Family
ID=40342626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010530124A Expired - Fee Related JP5669581B2 (ja) | 2007-10-18 | 2008-10-16 | 前立腺癌を処置するためのｍｖａの使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US7867483B2 (enExample) |
| EP (1) | EP2207564B1 (enExample) |
| JP (1) | JP5669581B2 (enExample) |
| KR (2) | KR101648087B1 (enExample) |
| CN (1) | CN101888853B (enExample) |
| AU (1) | AU2008312444B2 (enExample) |
| CA (1) | CA2702586C (enExample) |
| DK (1) | DK2207564T3 (enExample) |
| ES (1) | ES2608604T3 (enExample) |
| IL (1) | IL204541A (enExample) |
| NZ (2) | NZ584042A (enExample) |
| RU (1) | RU2499606C2 (enExample) |
| WO (1) | WO2009052328A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6136311A (en) | 1996-05-06 | 2000-10-24 | Cornell Research Foundation, Inc. | Treatment and diagnosis of cancer |
| DE20122302U1 (de) * | 2000-11-23 | 2005-02-24 | Bavarian Nordic A/S | Variante des Modifizierten Vaccinia-Ankara-Virus |
| WO2007109321A2 (en) | 2006-03-20 | 2007-09-27 | The Regents Of The University Of California | Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting |
| CA2698343C (en) | 2007-09-04 | 2018-06-12 | The Regents Of The University Of California | High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection |
| EP2740490A1 (en) * | 2007-10-03 | 2014-06-11 | Cornell University | Treatment of proliferative disorders using antibodies to PSMA |
| WO2009052328A1 (en) * | 2007-10-18 | 2009-04-23 | Bn Immunotherapeutics Inc. | Use of mva to treat prostate cancer |
| US20100069616A1 (en) * | 2008-08-06 | 2010-03-18 | The Regents Of The University Of California | Engineered antibody-nanoparticle conjugates |
| EP2398504B1 (en) * | 2009-02-17 | 2018-11-28 | Cornell Research Foundation, Inc. | Methods and kits for diagnosis of cancer and prediction of therapeutic value |
| GB2484058A (en) * | 2009-12-01 | 2012-04-04 | Uni Konstanz | Prostate cancer DNA vaccine |
| US8772459B2 (en) | 2009-12-02 | 2014-07-08 | Imaginab, Inc. | J591 minibodies and Cys-diabodies for targeting human prostate specific membrane antigen (PSMA) and methods for their use |
| US9575053B2 (en) | 2012-03-30 | 2017-02-21 | Kyoto University | Urinary biomarker for use in test for prostate cancer |
| KR102196884B1 (ko) * | 2013-11-01 | 2020-12-30 | 화이자 인코포레이티드 | 전립선-연관 항원의 발현을 위한 벡터 |
| KR20170083534A (ko) | 2014-09-19 | 2017-07-18 | 리제너론 파마슈티칼스 인코포레이티드 | 키메라 항원 수용체 |
| WO2016144564A2 (en) | 2015-02-25 | 2016-09-15 | Memorial Sloan-Kettering Cancer Center | Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors |
| CN107847534B (zh) | 2015-04-17 | 2022-10-04 | 纪念斯隆凯特琳癌症中心 | Mva或mvaδe3l作为抗实体瘤的免疫治疗剂的应用 |
| ES3020458T3 (en) | 2015-08-07 | 2025-05-22 | Imaginab Inc | Antigen binding constructs to target molecules |
| BR112018006263A2 (pt) * | 2015-10-02 | 2018-10-16 | Memorial Sloan Kettering Cancer Center | inibidor de tonsl, molécula pequena, uso de uma molécula pequena ou de um inibidor, cristal tridimensional, métodos para selecionar ou desenhar uma molécula pequena, para identificar um inibidor de ligação de ard de tonsl à histona h4, para predizer o efeito de inibição de tonsl e para identificar um inibidor de tonsl e/ou determinar o efeito inibitório de um inibidor putativo de tonsl, sequência de polinucleotídeo ou sequência de aminoácidos isolada, e, polipeptídeo mutante de tonsl. |
| FR3042121A1 (fr) | 2015-10-08 | 2017-04-14 | Jean-Marc Limacher | Composition anti-tumorale |
| GB201520570D0 (en) * | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520550D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520568D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd | Peptides |
| AU2017217940B2 (en) * | 2016-02-12 | 2024-03-21 | Madison Vaccines Inc. | Cancer therapy |
| IL261321B2 (en) | 2016-02-25 | 2023-12-01 | Memorial Sloan Kettering Cancer Center | Recombinant MVA or MVADELE3L expressing human FLT3L and their use as immunotherapeutic agents against solid tumors |
| SG11201807051VA (en) | 2016-02-25 | 2018-09-27 | Memorial Sloan Kettering Cancer Center | Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy |
| CA3021947A1 (en) * | 2016-04-26 | 2017-11-02 | Sumitomo Dainippon Pharma Co., Ltd. | Substituted purine derivative |
| IL263160B2 (en) | 2016-06-03 | 2024-01-01 | Regeneron Pharma | Non-human animals expressing exogenous terminal deoxynucleotidyltransferase |
| WO2017210562A1 (en) * | 2016-06-03 | 2017-12-07 | Etubics Corporation | Compositions and methods for tumor vaccination using prostate cancer-associated antigens |
| CN106084027A (zh) * | 2016-06-24 | 2016-11-09 | 安徽未名细胞治疗有限公司 | 特异性肿瘤抗原EphA2的CTL识别表位肽及其应用 |
| CN106119231A (zh) * | 2016-06-24 | 2016-11-16 | 安徽未名细胞治疗有限公司 | 一种肿瘤抗原psa的ctl识别表位肽及其应用 |
| US11266745B2 (en) | 2017-02-08 | 2022-03-08 | Imaginab, Inc. | Extension sequences for diabodies |
| WO2018209315A1 (en) | 2017-05-12 | 2018-11-15 | Memorial Sloan Kettering Cancer Center | Vaccinia virus mutants useful for cancer immunotherapy |
| US10925947B2 (en) * | 2018-06-29 | 2021-02-23 | Immatics Biotechnologies Gmbh | A*03 restricted peptides for use in immunotherapy against cancers and related methods |
| CN116162654A (zh) | 2018-09-15 | 2023-05-26 | 纪念斯隆凯特琳癌症中心 | 用于癌症免疫疗法的重组痘病毒 |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| JP2022536122A (ja) * | 2019-06-07 | 2022-08-12 | オレゴン ヘルス アンド サイエンス ユニバーシティ | 腫瘍関連抗原特異的ｔ細胞応答 |
| EP4061405A1 (en) | 2019-11-18 | 2022-09-28 | Janssen Biotech, Inc. | Vaccines based on mutant calr and jak2 and their uses |
| WO2021209897A1 (en) * | 2020-04-13 | 2021-10-21 | Janssen Biotech, Inc. | Psma and steap1 vaccines and their uses |
| EP4175664A2 (en) * | 2020-07-06 | 2023-05-10 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| FR3160186A1 (fr) | 2024-03-13 | 2025-09-19 | Odimma Therapeutics | Vecteur non-viral pour transcription augmentee |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69225710T3 (de) * | 1991-07-25 | 2004-10-14 | Idec Pharmaceuticals Corp., San Diego | Anregung von antworten zytotoxischer t-lymphozyten |
| AU686660B2 (en) * | 1993-08-11 | 1998-02-12 | Jenner Technologies | Prostatic cancer vaccine |
| US6045802A (en) * | 1994-10-03 | 2000-04-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule |
| US6165460A (en) * | 1995-07-10 | 2000-12-26 | Therion Biologics Corporation | Generation of immune responses to prostate-specific antigen (PSA) |
| WO1998004689A1 (en) * | 1995-07-31 | 1998-02-05 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
| WO1998046769A1 (en) | 1997-04-11 | 1998-10-22 | Dendreon Corporation | Composition and method for inducing an immune response against tumour-related antigens |
| DE69918146T2 (de) | 1998-10-05 | 2005-07-07 | Pharmexa A/S | Verfahren zur therapeutischen impfung |
| EP1137792B9 (en) * | 1998-12-09 | 2007-12-12 | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | A recombinant vector expressing multiple costimulatory molecules and uses thereof |
| DE20122302U1 (de) | 2000-11-23 | 2005-02-24 | Bavarian Nordic A/S | Variante des Modifizierten Vaccinia-Ankara-Virus |
| AU2003219983A1 (en) * | 2002-03-01 | 2003-09-16 | Applied Immune Technologies | Immunotherapy for prostate cancer using recombinant bacille calmette-guerin expressing prostate specific antigens |
| EP2253709B1 (en) * | 2002-05-16 | 2018-04-11 | Bavarian Nordic A/S | Recombinant poxvirus expressing homologous genes inserted into the poxviral genome |
| JP2007502602A (ja) * | 2003-08-21 | 2007-02-15 | バイラックス・ディベロップメント・プロプライエタリー・リミテッド | 前立腺癌の治療用の前立腺特異的抗原をコードするポックスウィルスベクター |
| BRPI0401465A (pt) | 2004-04-20 | 2006-02-21 | Embria Informatica Ltda | sistema para administrar interações entre usuários e aplicações de software em um ambiente web |
| WO2009052328A1 (en) | 2007-10-18 | 2009-04-23 | Bn Immunotherapeutics Inc. | Use of mva to treat prostate cancer |
-
2008
- 2008-10-16 WO PCT/US2008/080229 patent/WO2009052328A1/en not_active Ceased
- 2008-10-16 DK DK08839145.3T patent/DK2207564T3/en active
- 2008-10-16 CN CN2008801193517A patent/CN101888853B/zh not_active Expired - Fee Related
- 2008-10-16 NZ NZ584042A patent/NZ584042A/xx not_active IP Right Cessation
- 2008-10-16 NZ NZ601827A patent/NZ601827A/en not_active IP Right Cessation
- 2008-10-16 JP JP2010530124A patent/JP5669581B2/ja not_active Expired - Fee Related
- 2008-10-16 KR KR1020107010873A patent/KR101648087B1/ko not_active Expired - Fee Related
- 2008-10-16 US US12/253,094 patent/US7867483B2/en not_active Expired - Fee Related
- 2008-10-16 ES ES08839145.3T patent/ES2608604T3/es active Active
- 2008-10-16 AU AU2008312444A patent/AU2008312444B2/en not_active Ceased
- 2008-10-16 EP EP08839145.3A patent/EP2207564B1/en not_active Not-in-force
- 2008-10-16 CA CA2702586A patent/CA2702586C/en not_active Expired - Fee Related
- 2008-10-16 RU RU2010115220/15A patent/RU2499606C2/ru not_active IP Right Cessation
- 2008-10-16 KR KR1020167013629A patent/KR20160065985A/ko not_active Ceased
-
2010
- 2010-03-16 IL IL204541A patent/IL204541A/en active IP Right Grant
- 2010-08-30 US US12/871,017 patent/US8377688B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011500718A5 (enExample) | ||
| Moore et al. | Progress in DNA‐based heterologous prime‐boost immunization strategies for malaria | |
| Verardi et al. | A vaccinia virus renaissance: new vaccine and immunotherapeutic uses after smallpox eradication | |
| Guse et al. | Oncolytic vaccinia virus for the treatment of cancer | |
| Bridle et al. | Oncolytic vesicular stomatitis virus quantitatively and qualitatively improves primary CD8+ T-cell responses to anticancer vaccines | |
| EP2958994B1 (en) | Vaccine composition | |
| US9707285B2 (en) | Vaccination methods | |
| RU2010115220A (ru) | Применение mva (модифицированный вирус коровьей оспы анкара) для лечения рака простаты | |
| Webster et al. | Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers | |
| WO2015106697A1 (zh) | 免疫增强的人乳头瘤病毒感染及相关疾病的治疗性疫苗 | |
| JP2020528911A5 (enExample) | ||
| JP2024105526A (ja) | 免疫応答を誘導するための組成物 | |
| US8734806B2 (en) | Immunogenic composition and use thereof | |
| JP2018517419A5 (enExample) | ||
| Bubenik et al. | Interleukin 2 gene therapy of residual disease in mice carrying tumours induced by HPV 16. | |
| RU2018101722A (ru) | Днк-вакцина, нацеленная на vegfr-2, для комбинированной терапии | |
| Chen et al. | Optimisation of prime–boost immunization in mice using novel protein-based and recombinant vaccinia (Tiantan)-based HBV vaccine | |
| Beilvert et al. | DNA/amphiphilic block copolymer nanospheres reduce asthmatic response in a mouse model of allergic asthma | |
| Marcos-Villar et al. | Heterologous mRNA/MVA delivering trimeric-RBD as effective vaccination regimen against SARS-CoV-2: COVARNA Consortium | |
| Wang et al. | Involvement of CD8+ T cell-mediated immune responses in LcrV DNA vaccine induced protection against lethal Yersinia pestis challenge | |
| Ren et al. | Successive site translocating inoculation potentiates DNA/recombinant vaccinia vaccination | |
| RU2019125436A (ru) | Новый подход к иммунотерапии, нацеленной на vegfr-2 | |
| JP7454320B2 (ja) | アジュバントとしての腫瘍溶解性ウイルス | |
| Ding et al. | Evaluation of tumor specificity and immunity of thymidine kinase-deleted vaccinia virus guang9 strain | |
| Yang et al. | Immunization with virus-like vesicle-based COVID-19 vaccine induces robust systemic and mucosal immunity |